The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparison of Oncotype Dx (ODx) 21-gene recurrence score (RS) in African American (AA) and Caucasian (C) patients with hormone receptor-positive (HR+), HER2-negative (HER2-), lymph node-negative (LNN) breast cancer (BC).
K. B. Kabaker
No relevant relationships to disclose
J. Canar
No relevant relationships to disclose
R. D. Rao
No relevant relationships to disclose
M. A. Cobleigh
Consultant or Advisory Role - Genomic Health